TN2013000245A1 - Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib - Google Patents

Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib

Info

Publication number: TN2013000245A1
Authority: TN; Tunisia
Prior art keywords: bortezomib; containing antibodies; antibodies recognizing; combinations containing; recognizing specifically
Prior art date: 2010-12-10

Application number

TNP2013000245A

Other languages

English (en)

Inventor

Jutta Deckert

Pascale Lejeune

Michele F Mayo

Peter U Park

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-10

Filing date

2013-06-07

Publication date

2014-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44168449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000245(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-07 Application filed by Sanofi Sa filed Critical Sanofi Sa

2014-11-10 Publication of TN2013000245A1 publication Critical patent/TN2013000245A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2013000245A 2010-12-10 2013-06-07 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib TN2013000245A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP10306395		2010-12-10
PCT/EP2011/072228 WO2012076663A1 (fr)	2010-12-10	2011-12-08	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement le cd38 et du bortézomib

Publications (1)

Publication Number	Publication Date
TN2013000245A1 true TN2013000245A1 (en)	2014-11-10

Family

ID=44168449

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000245A TN2013000245A1 (en)	2010-12-10	2013-06-07	Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib

Country Status (42)

Country	Link
US (1)	US9314522B2 (fr)
EP (2)	EP2648747B1 (fr)
JP (1)	JP6177133B2 (fr)
KR (1)	KR101905208B1 (fr)
CN (2)	CN103282050B (fr)
AR (1)	AR084196A1 (fr)
AU (1)	AU2011340472B2 (fr)
BR (1)	BR112013014370B1 (fr)
CA (1)	CA2820382C (fr)
CL (1)	CL2013001670A1 (fr)
CO (1)	CO6801634A2 (fr)
CR (1)	CR20130270A (fr)
CY (1)	CY1121179T1 (fr)
DK (1)	DK2648747T3 (fr)
DO (1)	DOP2013000132A (fr)
EA (2)	EA026406B1 (fr)
EC (1)	ECSP13012669A (fr)
ES (1)	ES2694784T3 (fr)
GT (1)	GT201300147A (fr)
HR (1)	HRP20181787T1 (fr)
HU (1)	HUE039893T2 (fr)
IL (1)	IL226756B (fr)
LT (1)	LT2648747T (fr)
MA (1)	MA34816B1 (fr)
MX (2)	MX345257B (fr)
MY (1)	MY165109A (fr)
NI (1)	NI201300050A (fr)
NZ (1)	NZ612055A (fr)
PE (1)	PE20140004A1 (fr)
PH (1)	PH12013501183A1 (fr)
PL (1)	PL2648747T3 (fr)
PT (1)	PT2648747T (fr)
RS (1)	RS57997B1 (fr)
SG (2)	SG10201600985XA (fr)
SI (1)	SI2648747T1 (fr)
TN (1)	TN2013000245A1 (fr)
TR (1)	TR201816532T4 (fr)
TW (1)	TWI596116B (fr)
UA (1)	UA112170C2 (fr)
UY (1)	UY33791A (fr)
WO (1)	WO2012076663A1 (fr)
ZA (1)	ZA201304845B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2191843A1 (fr) *	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
AU2011310696B2 (en)	2010-09-27	2016-06-02	Morphosys Ag	Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
UA112170C2 (uk)	2010-12-10	2016-08-10	Санофі	Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
LT2900232T (lt)	2012-09-25	2018-02-26	Morphosys Ag	Deriniai ir jų panaudojimas
PL2968555T3 (pl) *	2013-03-13	2020-11-16	Sanofi	Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
WO2015014659A1 (fr) *	2013-08-02	2015-02-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps anti-claudin 1 et leurs utilisations
UA120748C2 (uk) *	2013-10-31	2020-02-10	Санофі	Спосіб лікування суб'єкта-людини з рецидивною і/або резистентною множинною мієломою, антитілом, що специфічно зв'язує cd38
US20150118251A1 (en) *	2013-10-31	2015-04-30	Sanofi	Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
WO2016022589A2 (fr)	2014-08-08	2016-02-11	The Regents Of The University Of California	Méthodes de traitement du myélome multiple
SG11201701867SA (en)	2014-09-09	2017-04-27	Janssen Biotech Inc	Combination therapies with anti-cd38 antibodies
PE20171094A1 (es)	2014-12-04	2017-08-07	Janssen Biotech Inc	Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CA2986594C (fr)	2015-05-20	2025-06-10	Tufts Medical Center Inc	Anticorps anti-cd38 pour le traitement de l’amyloïdose à chaînes légères et d’autres tumeurs malignes hématologiques positives à cd38
UA125115C2 (uk)	2015-06-22	2022-01-12	Янссен Байотек, Інк.	Спосіб лікування суб'єкта, який має множинну мієлому (мм)
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
HRP20220680T1 (hr)	2015-11-03	2022-07-08	Janssen Biotech, Inc.	Potkožne formulacije protutijela anti-cd38 i njihove uporabe
CN117330747A (zh)	2016-07-15	2024-01-02	武田药品工业株式会社	用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
KR102770106B1 (ko)	2017-06-08	2025-02-21	블랙 벨트 테라퓨틱스 리미티드	Cd38 조정 항체
CA3066547A1 (fr)	2017-06-08	2018-12-13	Black Belt Therapeutics Limited	Anticorps permettant de moduler cd38
KR102770110B1 (ko) *	2017-08-16	2025-02-20	블랙 벨트 테라퓨틱스 리미티드	Cd38 항체
WO2019035938A1 (fr)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	Molécules multispécifiques se liant à bcma et leurs utilisations
EP3668896A1 (fr)	2017-08-16	2020-06-24	Black Belt Therapeutics Limited	Anticorps modulateur cd38
US11542338B2 (en)	2017-08-16	2023-01-03	Black Belt Therapeutics Limited	CD38 modulating antibody
AU2018359527A1 (en)	2017-10-31	2020-05-07	Janssen Biotech, Inc.	Methods of treating high risk multiple myeloma
EP3737702A1 (fr)	2018-01-12	2020-11-18	Takeda Pharmaceutical Company Limited	Dosage sous-cutané d'anticorps anti-cd38
KR20210030411A (ko) *	2018-07-10	2021-03-17	사노피	Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법
US11655302B2 (en)	2019-06-10	2023-05-23	Sanofi	Anti-CD38 antibodies and formulations
TW202133879A (zh)	2019-12-05	2021-09-16	美商賽諾菲阿凡提斯美國有限責任公司	用於皮下投予之抗cd38抗體的調配物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB750155A (en)	1953-03-17	1956-06-13	Nat Res Dev	Substituted alanines
US3032585A (en)	1954-12-03	1962-05-01	Nat Res Dev	Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3116282A (en)	1960-04-27	1963-12-31	Upjohn Co	Pyrimidine nucleosides and process
US4281061A (en) *	1979-07-27	1981-07-28	Syva Company	Double antibody for enhanced sensitivity in immunoassay
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP1690935A3 (fr)	1990-01-12	2008-07-30	Abgenix, Inc.	Génération d'anticorps xenogéniques
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (fr)	1991-05-17	2005-02-23	Merck & Co. Inc.	Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
WO1992022653A1 (fr)	1991-06-14	1992-12-23	Genentech, Inc.	Procede de production d'anticorps humanises
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
KR100654645B1 (ko)	1995-04-27	2007-04-04	아브게닉스, 인크.	면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (fr)	1995-04-28	1996-10-31	Abgenix, Inc.	Anticorps humains derives de xeno-souris immunisees
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
DK1500329T3 (da)	1996-12-03	2012-07-09	Amgen Fremont Inc	Humane antistoffer, der specifikt binder TNF-alfa
KR100663319B1 (ko)	1997-04-14	2007-01-02	마이크로메트 에이지	인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
WO1999062526A2 (fr)	1998-06-05	1999-12-09	Mayo Foundation For Medical Education And Research	Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
DE19826517B4 (de)	1998-06-15	2006-03-23	Baxter Healthcare S.A.	Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
US7223397B1 (en)	1999-01-07	2007-05-29	Research Development Foundation	Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en)	2002-09-17	2002-10-23	Isis Innovation	Treatments
HUE025369T2 (en)	2004-02-06	2016-02-29	Morphosys Ag	Human antibodies against CD38 and their use
JP4912597B2 (ja)	2004-07-13	2012-04-11	パナソニック株式会社	液晶表示装置
US20080057070A1 (en)	2004-11-04	2008-03-06	Chiron Corporation	Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EA015584B1 (ru) *	2005-03-23	2011-10-31	Генмаб А/С	Антитело к cd38 человека и его применение
NZ576122A (en) *	2006-09-26	2012-09-28	Genmab As	Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
HRP20180873T1 (hr)	2007-08-29	2018-07-13	Sanofi	Humanizirana anti-cxcr5 protutijela, njihovi derivati i njihova upotreba
AU2009206506B2 (en)	2008-01-23	2013-01-10	Xencor, Inc.	Optimized CD40 antibodies and methods of using the same
EP2191842A1 (fr) *	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
EP2191841A1 (fr) *	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
EP2191840A1 (fr) *	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
EP2191843A1 (fr)	2008-11-28	2010-06-02	Sanofi-Aventis	Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
AU2011310696B2 (en) *	2010-09-27	2016-06-02	Morphosys Ag	Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
UA112170C2 (uk)	2010-12-10	2016-08-10	Санофі	Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
US8542056B2 (en) *	2010-12-27	2013-09-24	Stmicroelectronics S.Rl.	High voltage transmission switch, namely for ultrasound applications
US10342869B2 (en)	2012-12-07	2019-07-09	The Regents Of The University Of California	Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk)	2012-12-07	2018-12-26	Санофі	Композиція, яка містить антитіло до cd38 і леналідомід
PL2968555T3 (pl)	2013-03-13	2020-11-16	Sanofi	Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
US20150118251A1 (en)	2013-10-31	2015-04-30	Sanofi	Specific anti-cd38 antibodies for treating human cancers

2011
- 2011-08-12 UA UAA201308680A patent/UA112170C2/uk unknown
- 2011-12-07 AR ARP110104584A patent/AR084196A1/es unknown
- 2011-12-08 PE PE2013001392A patent/PE20140004A1/es active IP Right Grant
- 2011-12-08 PH PH1/2013/501183A patent/PH12013501183A1/en unknown
- 2011-12-08 KR KR1020137017923A patent/KR101905208B1/ko active Active
- 2011-12-08 SG SG10201600985XA patent/SG10201600985XA/en unknown
- 2011-12-08 CN CN201180064549.1A patent/CN103282050B/zh active Active
- 2011-12-08 JP JP2013542546A patent/JP6177133B2/ja active Active
- 2011-12-08 CA CA2820382A patent/CA2820382C/fr not_active Expired - Fee Related
- 2011-12-08 EA EA201390850A patent/EA026406B1/ru not_active IP Right Cessation
- 2011-12-08 MX MX2013006566A patent/MX345257B/es active IP Right Grant
- 2011-12-08 DK DK11801669.0T patent/DK2648747T3/en active
- 2011-12-08 MA MA36092A patent/MA34816B1/fr unknown
- 2011-12-08 SI SI201131609T patent/SI2648747T1/sl unknown
- 2011-12-08 WO PCT/EP2011/072228 patent/WO2012076663A1/fr not_active Ceased
- 2011-12-08 EP EP11801669.0A patent/EP2648747B1/fr active Active
- 2011-12-08 HR HRP20181787TT patent/HRP20181787T1/hr unknown
- 2011-12-08 US US13/992,684 patent/US9314522B2/en active Active
- 2011-12-08 HU HUE11801669A patent/HUE039893T2/hu unknown
- 2011-12-08 PT PT11801669T patent/PT2648747T/pt unknown
- 2011-12-08 LT LTEP11801669.0T patent/LT2648747T/lt unknown
- 2011-12-08 AU AU2011340472A patent/AU2011340472B2/en active Active
- 2011-12-08 BR BR112013014370-3A patent/BR112013014370B1/pt active IP Right Grant
- 2011-12-08 TR TR2018/16532T patent/TR201816532T4/tr unknown
- 2011-12-08 ES ES11801669.0T patent/ES2694784T3/es active Active
- 2011-12-08 NZ NZ612055A patent/NZ612055A/en unknown
- 2011-12-08 CN CN201610701653.1A patent/CN106334187B/zh active Active
- 2011-12-08 RS RS20181352A patent/RS57997B1/sr unknown
- 2011-12-08 SG SG2013044144A patent/SG191059A1/en unknown
- 2011-12-08 PL PL11801669T patent/PL2648747T3/pl unknown
- 2011-12-08 EP EP18180404.8A patent/EP3412311A1/fr not_active Withdrawn
- 2011-12-08 MY MYPI2013002090A patent/MY165109A/en unknown
- 2011-12-08 EA EA201692047A patent/EA201692047A1/ru unknown
- 2011-12-08 MX MX2017001016A patent/MX393853B/es unknown
- 2011-12-09 TW TW100145632A patent/TWI596116B/zh active
- 2011-12-09 UY UY0001033791A patent/UY33791A/es not_active Application Discontinuation
2013
- 2013-06-05 IL IL226756A patent/IL226756B/en active IP Right Grant
- 2013-06-06 CO CO13137654A patent/CO6801634A2/es not_active Application Discontinuation
- 2013-06-06 NI NI201300050A patent/NI201300050A/es unknown
- 2013-06-06 GT GT201300147A patent/GT201300147A/es unknown
- 2013-06-07 TN TNP2013000245A patent/TN2013000245A1/fr unknown
- 2013-06-07 CR CR20130270A patent/CR20130270A/es unknown
- 2013-06-07 EC ECSP13012669 patent/ECSP13012669A/es unknown
- 2013-06-10 CL CL2013001670A patent/CL2013001670A1/es unknown
- 2013-06-10 DO DO2013000132A patent/DOP2013000132A/es unknown
- 2013-06-28 ZA ZA2013/04845A patent/ZA201304845B/en unknown
2018
- 2018-11-08 CY CY20181101180T patent/CY1121179T1/el unknown

Also Published As

Publication number	Publication date
CY1121179T1 (el)	2020-05-29
HUE039893T2 (hu)	2019-02-28
UA112170C2 (uk)	2016-08-10
SI2648747T1 (sl)	2019-04-30
CN103282050B (zh)	2016-09-07
AR084196A1 (es)	2013-04-24
ZA201304845B (en)	2014-09-25
UY33791A (es)	2012-07-31
CN106334187B (zh)	2021-02-12
MA34816B1 (fr)	2014-01-02
PT2648747T (pt)	2018-11-21
NZ612055A (en)	2014-12-24
MX345257B (es)	2017-01-23
PE20140004A1 (es)	2014-01-23
WO2012076663A1 (fr)	2012-06-14
MY165109A (en)	2018-02-28
MX393853B (es)	2025-03-24
DK2648747T3 (en)	2018-12-03
TWI596116B (zh)	2017-08-21
EP2648747B1 (fr)	2018-08-08
NI201300050A (es)	2013-08-01
EA201390850A1 (ru)	2013-12-30
US9314522B2 (en)	2016-04-19
LT2648747T (lt)	2018-11-26
CR20130270A (es)	2013-09-03
MX2013006566A (es)	2013-08-26
GT201300147A (es)	2017-12-15
RS57997B1 (sr)	2019-01-31
CN106334187A (zh)	2017-01-18
EP2648747A1 (fr)	2013-10-16
BR112013014370A2 (pt)	2017-05-30
CL2013001670A1 (es)	2014-02-28
AU2011340472A1 (en)	2013-05-02
CO6801634A2 (es)	2013-11-29
TW201307392A (zh)	2013-02-16
JP2014502280A (ja)	2014-01-30
PH12013501183A1 (en)	2013-07-15
SG10201600985XA (en)	2016-03-30
US20140186337A1 (en)	2014-07-03
EA026406B1 (ru)	2017-04-28
BR112013014370B1 (pt)	2020-12-01
EP3412311A1 (fr)	2018-12-12
CA2820382A1 (fr)	2012-06-14
CN103282050A (zh)	2013-09-04
IL226756B (en)	2020-06-30
KR20130130774A (ko)	2013-12-02
KR101905208B1 (ko)	2018-10-05
ECSP13012669A (es)	2013-08-30
EA201692047A1 (ru)	2017-06-30
JP6177133B2 (ja)	2017-08-09
SG191059A1 (en)	2013-08-30
AU2011340472B2 (en)	2015-02-12
HRP20181787T1 (hr)	2018-12-28
ES2694784T3 (es)	2018-12-27
PL2648747T3 (pl)	2019-01-31
TR201816532T4 (tr)	2018-11-21
CA2820382C (fr)	2020-08-18
DOP2013000132A (es)	2013-09-30

Publication	Publication Date	Title
TN2013000245A1 (en)	2014-11-10	Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
TN2011000163A1 (en)	2012-12-17	Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
TN2011000232A1 (en)	2012-12-17	Antitumor combinations containing antibodies recognizing specifically cd38 melphalan
MY166530A (en)	2018-07-10	Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamide
TN2011000242A1 (en)	2012-12-17	Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
MX336682B (es)	2016-01-27	Anticuerpos contra csf-1r humanos y usos de los mismos.
IN2015DN02349A (fr)	2015-08-28
PH12013500432A1 (en)	2017-08-23	Anti-vegfr-3 antibody compositions
TN2011000153A1 (en)	2012-09-05	Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
TN2013000068A1 (en)	2014-06-25	Anti-vegfr-3 antibody compositions